Skip to main content


Scroll down

RePHILL – a patient’s view

Published on 18/01/2021

Jacob Coxon

A UK trial looking at the effectiveness of giving blood to trauma patients before they come to hospital has recently finished recruitment, and one of the participants recently told us his story.

The Resuscitation with pre-hospital blood products (RePHILL) trial has recruited more than 400 patients, with recruitment ending in December 2020.

Jacob Coxon, who was the 66th person to take part in the trial, said: “In early 2019 I was involved in a severe car crash and was taken to the QE with extensive head injuries including facial fractures and eye damage.

“Although I am now registered blind, I do have peripheral vision in one eye, and my broken bones have healed.

“There are many people who helped me when I was in hospital but I’d particularly like to thank to all the staff in Critical Care C & Ward 407 at the Queen Elizabeth Hospital Birmingham for their kindness and care.

“I only found out I’d taken part in RePHILL once I was in hospital, but am pleased to have played my part in the trial.

“I think anyone who can should take part in research. It could make all the difference for millions of people in the future.”

RePHILL is run by the NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC) and includes a number of partner organisations, including University Hospitals Birmingham NHS Foundation Trust (UHB) and the University of Birmingham.

Nick Crombie, UHB Associate Medical Director and co-Chief Investigator of the trial, said: “Thanks to patients like Jake, we hope to find out if giving blood to trauma patients who have suffered a major injury is beneficial.

“Trial recruitment has involved true partnership working, with everyone involved playing a key role in keeping the trial running.

“With recruitment now finished, we will be able to publish the long-awaited results in the coming months.”

Patients who took part in RePHILL received either red blood cells and plasma or saline, the current standard care, and were monitored for 30 days post-trauma.